Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties

The use of Lenalidomide (LEN), to reverse tumor-mediated immune suppression and amplify multiple myeloma-specific immunity is currently being explored. Particularly, LEN effects on dendritic cells (DCs) are still unclear. In this study, we investigated the potential effect of LEN on DC differentiati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Costa, Federica, Vescovini, Rosanna, Bolzoni, Marina, Marchica, Valentina, Storti, Paola, Toscani, Denise, Accardi, Fabrizio, Notarfranchi, Laura, Dalla Palma, Benedetta, Manferdini, Cristina, Manni, Sabrina, Todaro, Giannalisa, Lisignoli, Gina, Piazza, Francesco, Aversa, Franco, Giuliani, Nicola
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581092/
https://ncbi.nlm.nih.gov/pubmed/28881793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18085
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky